Jaiwant Rangi, MD, FACEEndocrinologist | Founder, Lower The Dose® | Speaker

The New Frontiers of Diabetes and Cardiovascular Health

31 Jul 2026 · 1 min

Watch on YouTube

0:46

In this educational segment, Dr. Jaiwant Rangi introduces two recently approved diabetes medication classes—GLP‑1 receptor agonists and SGLT2 inhibitors—and explains why they have transformed cardiovascular care. He emphasizes that the talk is not a prescription and that treatment decisions belong to patients and their clinicians. GLP‑1 agonists improve endogenous insulin utilization, suppress appetite, promote weight loss, and, in large outcome trials, have cut major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by roughly 10‑20%. Some agents in this class also demonstrate slowing of kidney disease progression. The SGLT2 inhibitor class is mentioned as the other game‑changing group, setting the stage for later discussion of its mechanisms and benefits.

Chapters

So this is going to be complex, but I'm trying to simplify it as much as possible. I'll speak in categories, and this is education. It's not a prescription for anyone. Your plan is always between you and your clinician, so don't think this is a plan for you. So two newer classes changed the game. One is called GLP-1 agonists, and the other one is called SGLT2 inhibitors. The GLP-1 class helps the body use its own insulin, calm the appetite, support the weight loss, and in large trials has reduced heart attacks, strokes, cardiovascular death by roughly 10 to 20%. And some of these drugs have also been shown to slow the kidney disease.